References
- Bindra R, Heath V, Liao A, et al. One-stop clinic for assessment of risk for trisomy 21 at 11–14 weeks: a prospective study of 15 030 pregnancies. Ultrasound in Obstet Gynecol 2002;20:219–25
- Malone FD, D'Alton ME. First-trimester sonographic screening for Down syndrome. Obstet Gynecol 2003;102:1066–79
- Wapner R, Thom E, Simpson JL, et al. First-trimester screening for trisomies 21 and 18. New Engl J Med 2003;349:1405–13
- Gynecologists ACoOa. Screening for fetal chromosomal abnormalities. ACOG Practice Bulletin No. 77. Obstet Gynecol 2007;109:217–27
- Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 2004;191:1446–51
- D'Antonio F, Rijo C, Thilaganathan B, et al. Association between first-trimester maternal serum pregnancy-associated plasma protein-A and obstetric complications. Prenatal Diag 2013;33:839–47
- Krantz D, Goetzl L, Simpson JL, et al. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 2004;191:1452–8
- Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012;120:1532–4
- Nicolaides KH, Syngelaki A, Ashoor G, et al. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 2012;207:374 e1–6
- McElrath TF, Lim KH, Pare E, et al. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol 2012;207:407 e1–7
- Yudkin PL, Aboualfa M, Eyre JA, et al. New birthweight and head circumference centiles for gestational ages 24 to 42 weeks. Early Human Develop 1987;15:45–52
- Fetal growth restriction. Practice Bulletin No. 134. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;121:1122–33
- Pedersen JF, Sorensen S, Ruge S. Human placental lactogen and pregnancy-associated plasma protein A in first trimester and subsequent fetal growth. Acta Obstet Gynecol Scand 1995;74:505–8
- Ong CY, Liao AW, Spencer K, et al. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 2000;107:1265–70
- Tul N, Pusenjak S, Osredkar J, et al. Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. Prenatal Diag 2003;23:990–6
- Yaron Y, Heifetz S, Ochshorn Y, et al. Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenatal Diag 2002;22:778–82
- Smith GC, Stenhouse EJ, Crossley JA, et al. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. JClin Endocrinol Metabol 2002;87:1762–7
- Benn P, Borrell A, Crossley J, et al. Aneuploidy screening: a position statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, January 2011. Prenatal Diag 2011;31:519–22